In aberrant hematopoiesis, such as in acute myeloid leukemia (AML), upregulated expression of DLX1 has been recorded as a downstream effect of activating mutations of fms-like tyrosine kinase 3 (FLT3), a frequent genomic alteration (~30%) that accompanies AML phenotypes [114,115]. Here, DLX1 is linked to acute myeloid leukemia.